

<p style="text-align: center;">LIST OF PRIOR ART CITED BY APPLICANT (PTO-1449)</p> <p style="text-align: center;">SEP 21 2004</p> <p style="text-align: center;">U.S. TRADEMARK OFFICE</p>	ATTY. DOCKET NO. CHNT-0015	APPLN. SERIAL NO. 10/804,214
	APPLICANT(S) Arthur M. Brown, Eckhard FICKER and Barbara A. WIBLE	
	CUSTOMER NO. 34610	
	FILING DATE March 19, 2004	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	*PATENT NO.	*ISSUE DATE	*INVENTOR NAME	CLASS	SUBCLASS	FILING DATE
GG	6,632,924	10/14/03	Bogan et al.	530	350	06/28/01
GG	6,303,373	10/16/01	Bogan et al.	435	325	06/09/00
GG	6,187,802	02/13/01	Cheetham et al.	514	370	03/09/98
GG	4,874,765	10/17/89	Lapis et al.	514	255	04/22/87
GG	4,476,129	10/09/84	Gootjes et al.	424	250	10/09/84
GG	4,202,896	05/13/80	Gootjes	424	250	05/13/80

U.S. PATENT APPLICATION PUBLICATIONS

	*PATENT APPLN. PUB. NO.	*PUB. DATE	*APPLICANT	CLASS	SUBCLASS

U.S. PATENT APPLICATIONS

	*APPLN. NO.	*FILING DATE	*INVENTOR	CLASS	SUBCLASS

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						Yes No
GG	WO 91/01732	02/21/91	WIPO			✓
GG	WO 98/18368	05/07/98	WIPO			✓
GG	0 243 903 B1	04/28/87	EPO			ABST

OTHER ART (Including Author, Title, Date, Pertinent Pages, Publisher, Place of Publication, Etc.)

GG	Maginn et al., "Protective Effects of Vanoxeamine (GBR 12909) Against Ischemia-Induced Hyperactivity and Neurodegeneration in the Gerbil Model of Cerebral Ischemia", Abstract, Pharmacology, Biochemistry and Behavior, 1997, 56(4), pp. 727-735.
GG	Thomas et al., "High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872", Abstract, Journal of Pharmacology and Experimental Therapeutics, 2001, 297(2), pp. 753-761.
GG	Nielsen-Kidsk et al., "Myocardial Accumulation Kinetics and Pharmacodynamics in the Isolated Rabbit Heart of a New Inhibitor of Dopamine Reuptake, GBR 12909," abstract, Pharmacology & Toxicology (Oxford, United Kingdom), 1990, 66(3), pp. 197-202.

EXAMINER	Gailene Gabel / (02/27/2007)	DATE CONSIDERED	02/27/2007
----------	------------------------------	-----------------	------------

**LIST OF PRIOR ART CITED BY
APPLICANT**
(PTO-1449)

ATTY. DOCKET NO.
CHNT-0015

APPLN. SERIAL NO.
10/804,214

APPLICANT(S) Arthur M. BROWN, Eckhard FICKER and
Barbara A. WIBLE

FILING DATE
March 19, 2004

GROUP
1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Publisher, Place of Publication, Etc.)

GG	W. TANG, et al., "Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel", October, 2001, pp. 325-331, Journal of Biomolecular Screening, Vol. 6, No. 5, Bridgewater, NJ.
GG	J. XU, et al., "Ion-channel Assay Technologies: quo vadis?", December, 2001, pp. 1278-1287, Drug Discovery Today, Vol. 6, No. 24.
GG	K. NG et al., "Engineering Protein-Lipid Interactions: Targeting of Histidine-Tagged Proteins to Metal-Chelating Lipid Monolayers", Langmuir, Vol. 11, 1995, pp. 4048-4055.
GG	W. SCHUHMANN et al., "Immobilization of Enzymes on Langmuir-Blodgett Films via a Membrane-Bound Receptor. Possible Applications for Amperometric Biosensors", Advanced Materials, Vol. 3, No. 7/8, 1991, pp. 388-391.
GG	L. SCHMITT et al., "Specific Protein Docking to Chelator Lipid Monolayers Monitored by FT-IR Spectroscopy at the Air-Water Interface", Angewandte Chemie Int. Edition in English, Vol. 35, No. 3, 1996, pp. 317-320.
GG	A. COLLILOUD et al., "Oriented and Covalent Immobilization of Target Molecules to Solid Supports: Synthesis and Application of a Light-Activatable and Thiol-Reactive Cross-Linking Reagent", Bioconjugate Chemistry, Vol. 4, No. 6, 1993, pp. 528-536.
GG	J. VANDENBERG et al., "HERG K ⁺ Channels: friend and foe", Trends Pharmacol. Sciences, Vol. 22, 2001, pp. 240-246.
GG	M. ROY, Ph.D., et al., "HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine", Circulation, Vol. 94, No. 4, August, 1996, pp. 817-823.
GG	K. FINLAYSON et al., "[³ H]Dofetilide Binding to HERG Transfected Membranes: a Potential High Throughput Preclinical Screen", Eur. Journal of Pharmacology, Vol. 430, No. 1, October, 2001, pp. 147-148.
GG	G. Terstappen, "Functional Analysis of Native and Recombinant Ion Channels Using a High-Capacity Nonradioactive Rubidium Efflux Assay", Analytical Biochemistry, Vol. 272, No. 2, August, 1999, pp. 149-155.
GG	B. LU et al., "Oriented Immobilization of Fab' Fragments on Silica Surfaces", Analytical Chemistry, Vol. 67, No. 1, January, 1995, pp. 83-87.
GG	A. IWANE et al., "Myosin Subfragment-1 Is Fully Equipped with Factors Essential for Motor Function", Biochemical and Biophysical Research Comm., Vol. 230, No. 1, January, 1997, pp. 76-80.
GG	W. FREY et al., "Two-Dimensional Protein crystallization via Metal-Ion Coordination by Naturally Occurring Surface Histidines", Proceedings of the Nat'l Academy of Sciences, Vol. 93, No. 10, May, 1996, pp. 4937-4941.
GG	E. KUBALEK et al., "Two Dimensional Crystallization of Histidine-Tagged, HIV-1 Reverse Transcriptase promoted by a Novel Nickel-Chelating Lipid", Journal of Structural Biology, Vol. 113, No. 2, 1994, pp. 117-123.
GG	G. SIGAL et al., "A Self-Assembled Monolayer for the Binding and Study of Histidine-Tagged Proteins by Surface Plasmon Resonance", Analytical Chemistry, Vol. 68, No. 3, February, 1996, pp. 490-497.
GG	M. FURUTANI et al., "Novel Mechanism Associated With an Inherited Cardiac Arrhythmia: Defective protein Trafficking by the Mutant HERG (G601S) Potassium Channel", Circulation, Vol. 99, No. 7, May, 1999, pp. 2290-2294.

EXAMINER
/Gailene Gabel/ (02/27/2007)

DATE CONSIDERED

02/27/2007

LIST OF PRIOR ART CITED BY APPLICANT (PTO-1449)		ATTY. DOCKET NO. CHNT-0015	APPLN. SERIAL NO. 10/804,214
		APPLICANT(S) Arthur M. BROWN, Eckhard FICKER and Barbara A. WIBLE	
		FILING DATE March 19, 2004	GROUP 1645
OTHER ART (Including Author, Title, Date, Pertinent Pages, Publisher, Place of Publication, Etc.)			
GG	Ficker et al, "The Binding Site for Channel Blockers that Rescue Misprocessed Human Long QT Syndrome Type 2 Ether-A-Gogo-Related Gene (HERG) Mutations," abstract, Journal of Biological Chemistry, 2002, 277(7), pp. 4989-4998.		
GG	Balser, J.R. et al., "Suppression of time-dependent outward current in Guinea Pig Ventricular Myocytes: Actions of quinidine and amiodarone", Circ. Res. 69:519-529 (1991)		
GG	Funck-Breton, C., "Rate-Dependence of Class III Actions in the Heart", Fundam Clin Pharmacol (1993), 7, 51-59.		
GG	Curran, M.E. et al., "A Molecular Basis for Cardiac arrhythmia: HERG Mutations Cause Long QT Syndrome", Cell 80: 795-803 (1995).		
GG	Dutta, A.K. et al., "Positional Importance of the Nitrogen Atom in Novel Piperidine Analogs of GBR 12909: Affinity and Selectivity for the Dopamine Transporter", Medical Chemistry Research, 3:209-222 (1993).		
GG	Hondegem, L. M., "Development of Class III Antiarrhythmic Agents", J. Cardiovasc. Pharmacol. 20 (Suppl. 2):S17-S22 (1992).		
GG	Hondegem, L. M. et al., "Class III Antiarrhythmic Agents Have a Lot of Potential but Long Way to go: reduced effectiveness and dangers of reverse use dependence", Circulation, 81:686-690 (1990).		
GG	Jurkiewicz, N.K. et al., "Rate-Dependent Prolongation of Cardiac Action Potentials by a Methanesulfonanilide Class III Antiarrhythmic Agent: Specific Block of Rapidly Activating Delayed Rectifier K ⁺ Current by Dofetilide", Circ. Res. 72:75-83 (1993).		
GG	Lewis, D.B. et al., "Oxygenated Analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as Potential Extended-Action Cocaine-Abuse Therapeutic Agents", J. Med. Chem. 42:5029-5042 (1999).		
GG	Nademanee, K., "The Amiodarone Odyssey", J. Am. Coll. Cardiol. 20:1063-1065 (1992).		
GG	Rodden, D.M., "Current Status of Class III Antiarrhythmic Drug Therapy", Am. J. Cardiol, 72:44B-49B (1993).		
GG	Sadanaga, T. et al., "Clinical Evaluation of the Use-Dependent QRS Prolongation and the Reverse Use-Dependent QT Prolongation of Class I and Class III Antiarrhythmic Agents and Their Value in Predicting Efficacy", Am. Heart J. 126:114-121 (1993).		
GG	Sanguineti, M.C. et al., "Two Components of Cardiac Delayed Rectifier K ⁺ Current: Differential Sensitivity to Block by Class III Antiarrhythmic Agents", J. Gen. Physiol. 96:195-215 (1990).		
GG	Singh B.N., et al., "The Effect of Amiodarone, a New Anti-Anginal Drug, on Cardiac Muscle", Br. J. Pharmacol 39:657-667 (1970).		
GG	Singh B.N., et al., "A Third Class of Anti-arrhythmic Action. Effects on atrial and ventricular intracellular Potentials, and Other Pharmacological Actions on Cardiac Muscle, of MJ 1999 and AH 3474", Br. J. Pharmacol. 39:675-687 (1970).		
GG	Williams, E.M., "Classification of Anti-arrhythmic Drugs", Symposium on Cardiac Arrhythmias, (Sandoe E. et al. (Editors)), Chapter 20, pp. 449-472 (1981).		
EXAMINER /Gailene Gabel/ (02/27/2007)		DATE CONSIDERED 02/27/2007	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.